Automatic and ambulatory monitoring of congestive heart failure patients

• US 8,475,387 B2
• Filed: 06/18/2007
• Issued: 07/02/2013
• Est. Priority Date: 06/20/2006
• Status: Active Grant

• Current Assignee: Adidas AG
• Original Assignee: Adidas AG
• Inventors: Derchak, P. Alexander, Lucia, Gary Michael, Myers, Lance Jonathan
• Primary Examiner(s): Holmes, Rex R
• Application Number:
  US11/764,527
• Publication Number:
  US 20080045815A1
• Time in Patent Office: 2,206 Days
• Field of Search: 607/6, 600/301, 600309-310, 600322-324, 600/529, 600/534
• US Class Current: 600/529
• CPC Class Codes: A61B 2562/0219 Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
• CPC Class Codes: A61B 5/0205 Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• CPC Class Codes: A61B 5/02405 Determining heart rate variability
• CPC Class Codes: A61B 5/11 Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb for measuring pulse A61B5/02 ;A61B5/1038 takes precedence; motion detection to correct for motion artifacts in physiological signals A61B5/721
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61B 5/7257 using Fourier transforms

Abstract

This invention provides methods for non-invasively monitoring patients with congestive heart failure (CHF) and for reporting and/or warning of changes in the patients'"'"' status. The methods gather physiological data and combine the data into parameters by which the severity of CHF can be judged. Preferred parameters include periodic breathing and heart rate variability. This invention also provides systems for carrying out these methods which permit patients to engage in their normal daily activities. Preferably, physiological data analysis is performed by a portable electronic unit carried by the patients.

Claims

1. A method for automatically monitoring congestive heart failure (CHF) in a subject comprising:

receiving signals, from a sensor, generated by non-invasively monitoring respiratory physiology of the subject, the signals conveying information concerning at least the subject'"'"'s breath rate and volume;

examining, with a processor, the received signals for determination of a minute ventilation (VE) signal and for indications of periodic breathing (PB), wherein the presence or absence of PB is determined through a multi-scale entropy analysis of the received signals and a power spectrum analysis of the VE signal;

indicating the status of CHF in the subject to be of increased severity if indications of PB are found.

2. The method of claim 1 wherein the VE signal is sampled at a fixed sampling rate.

3. The method of claim 2 wherein the step of examining further comprises:

forming an auto-correlogram by auto-correlating the VE signal at a zero temporal shift and at a plurality of non-zero temporal shifts; and

examining the auto-correlogram for indications of PB, PB being indicated if the auto-correlogram comprises a significant maximum at a non-zero temporal shift adjacent to the central maximum at zero temporal shift.

4. The method of claim 2 wherein the power spectrum analysis comprises:

forming a power spectrum by a Fourier transform method of the VE signal, the VE signal having been windowed; and

examining the power spectrum for indications of PB, PB being indicated if the power spectrum comprises a significant maximum at a frequency characteristic of PB.

5. The method of claim 2 wherein the power spectrum analysis comprises:

forming a power spectrum by a Lomb-Scargle method of the VE signal, the VE signal having been windowed; and

examining the power spectrum for indications of PB, PB being indicated if the power spectrum comprises a significant maximum at a frequency characteristic of PB.

6. The method of claim 2 wherein the power spectrum analysis comprises:

forming a power spectrum by a Burg method of the VE signal, the VE signal having been windowed; and

examining the power spectrum for indications of PB, PB being indicated if the power spectrum comprises a significant maximum at a frequency characteristic of PB.

7. The method of claim 1 wherein the received signals convey information concerning the time-varying sizes of one or both of the subject'"'"'s thorax (RC) and of the subject'"'"'s abdomen (AB), and

wherein the power spectrum analysis comprises forming a power spectrum of the received signals by one or more of an auto correlation method, a Fourier transform method, a Lomb-Scargle method, and a Burg method;

and

examining the power spectrum for indications of PB, PB being indicated if the power spectrum comprises two significant maxima, one at a frequency characteristic of PB and another at a frequency characteristic of respiration.

8. The method of claim 7 further comprising, prior to the step of forming a power spectrum, de-tending the received signals and rectifying the de-trended signals.

9. The method of claim 1 wherein the multi-scale entropy analysis further comprises:

calculating a plurality of entropies of a plurality of additional signals, the plurality of additional signals being derived from the received signals by performing windowing followed by a plurality of degrees of coarse graining; and

examining the plurality of entropies for indications of PB by comparing entropies at lesser degrees of coarse graining with entropies at greater degrees of coarse graining.

10. The method of claim 9 wherein one or more of the entropies are calculated according to the sample entropy method.

11. The method of claim 1, wherein examining the received signals further comprises examining the received signals for indications of reduced heart rate variability (HRV).

12. The method of claim 11, wherein indicating the status of CHF in the subject further comprises indicating the status of CHF in the subject in dependence on the indications of HRV.

13. The method of claim 1, wherein at least a portion of the signals are received when the subject is ambulatory.

14. The method of claim 12, wherein CHF is indicated to be of increased severity if indications of reduced HRV are found.

15. The method of claim 12, wherein the received signals also convey information concerning the magnitude of the subject'"'"'s cardiac pulsations;

wherein the received signals are examined for indications of cardiac output (CO), and wherein CHF is indicated to be of increased severity if indications of reduced CO are found.

16. The method of claim 12, wherein the received signals also convey information concerning the subject'"'"'s blood oxygen content (spO2), and wherein CHF is indicated to be of increased severity if indications of reduced spO2 are found.